Drug Information
| Drug General Information | Top | |||
|---|---|---|---|---|
| Drug ID |
D0B3GF
|
|||
| Former ID |
DNCL002133
|
|||
| Drug Name |
JNJ-26854165
|
|||
| Synonyms |
Serdemetan; 881202-45-5; N1-(2-(1H-Indol-3-yl)ethyl)-N4-(pyridin-4-yl)benzene-1,4-diamine; JNJ-26854165 (Serdemetan); UNII-ID6YB4W3V8; ID6YB4W3V8; C21H20N4; n-(2-(1h-indol-3-yl)ethyl)-n'-(4-pyridinyl)-1,4-benzenediamine; N-[2-(1H-INDOL-3-YL)ETHYL]-N'-(4-PYRIDINYL)-1,4-BENZENEDIAMINE; Serdemetan [INN]; MLS006011022; SCHEMBL3012498; CHEMBL2137530; CTK8C1936; EX-A267; DTXSID30236830; MolPort-009-679-468; HMS3654A16; JNJ 26854165 (Serdemetan); BCP02124; AOB87702; QC-534; ANW-67474
Click to Show/Hide
|
|||
| Drug Type |
Small molecular drug
|
|||
| Indication | Non-small-cell lung cancer [ICD-11: 2C25.Y] | Phase 1 | [1] | |
| Prostate cancer [ICD-11: 2C82.0] | Phase 1 | [1] | ||
| Solid tumour/cancer [ICD-11: 2A00-2F9Z; ICD-10: C76-C80; ICD-9: 140-229] | Phase 1 | [2] | ||
| Company |
Johnson & Johnson Pharmaceutical
|
|||
| Structure |
 |
Download2D MOL |
||
| Formula |
C21H20N4
|
|||
| Canonical SMILES |
C1=CC=C2C(=C1)C(=CN2)CCNC3=CC=C(C=C3)NC4=CC=NC=C4
|
|||
| InChI |
1S/C21H20N4/c1-2-4-21-20(3-1)16(15-24-21)9-14-23-17-5-7-18(8-6-17)25-19-10-12-22-13-11-19/h1-8,10-13,15,23-24H,9,14H2,(H,22,25)
|
|||
| InChIKey |
CEGSUKYESLWKJP-UHFFFAOYSA-N
|
|||
| CAS Number |
CAS 881202-45-5
|
|||
| PubChem Compound ID | ||||
| PubChem Substance ID |
16712431, 23719842, 80031113, 99437011, 124757051, 125163855, 125570991, 131480679, 135354294, 136367345, 137276015, 141237741, 141452097, 152258348, 160647186, 160834972, 162011792, 162037481, 162202718, 163096850, 163400762, 163845686, 164045297, 164127604, 164194047, 164779935, 174531178, 184815993, 188899564, 198947717, 204364943, 223377653, 223577219, 223705088, 229067315, 242060118, 243276763, 249867804, 250208779, 251963251, 252067977, 252215622, 252440638, 252451764
|
|||
| References | Top | |||
|---|---|---|---|---|
| REF 1 | ClinicalTrials.gov (NCT00676910) A Research Study of JNJ-26854165 to Determine the Safety and Dose in Patients With Advanced Stage or Refractory Solid Tumors.. U.S. National Institutes of Health. | |||
| REF 2 | Small molecules, big targets: drug discovery faces the protein-protein interaction challenge.Nat Rev Drug Discov. 2016 Aug;15(8):533-50. | |||
| REF 3 | Serdemetan antagonizes the Mdm2-HIF1alpha axis leading to decreased levels of glycolytic enzymes. PLoS One. 2013 Sep 6;8(9):e74741. | |||
If You Find Any Error in Data or Bug in Web Service, Please Kindly Report It to Dr. Zhou and Dr. Zhang.